FDA accepts Iveric Bio's NDA, grants priority review for GA drug
On the heels of a second Phase III win in geographic atrophy last year, Iveric Bio is now waiting at the FDA’s doors for its …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
